Janssen Reports Submission of BLA to the US FDA for the Approval of Teclistamab to Treat Multiple Myeloma
Shots:
- The BLA submission is based on the (MajesTEC-1) study to evaluate the safety and efficacy of teclistamab in adults with R/R multiple myeloma
- In the MajesTEC-1 study, investigators assessed efficacy outcomes, including ORR, VGPR, and CR using IMWG criteria along with the safety profile of teclistamab. The results were presented at ASH annual meeting
- Teclistamab is an investigational, off-the-shelf, T-cell redirecting, a bispecific antibody targeting BCMA and CD3 & is currently being evaluated in multiple monothx. & combination studies. The therapy also received ODD from the EC & US FDA for MM while PRIME designation from the EMA and BTD from the US FDA
Ref: PR Newswire | Image: Janssen
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com